The global crispr technology market size was valued at USD 4.5 billion in 2025 and is projected to grow from USD 5.32 billion in 2026 to USD 20.33 billion by 2034, registering a CAGR of 18.24% during the forecast period from 2026 to 2034. North America dominated the crispr technology market with a market share of 52.64% in 2025.
The CRISPR technology market is growing due to rising demand for precise gene editing in healthcare, agriculture, and biotechnology research. It enables targeted modification of genes for treating genetic disorders, improving cancer therapies, and supporting drug discovery. In agriculture, it helps develop crops with better yield, resistance, and quality. Continuous innovation improves accuracy, safety, and delivery methods, making applications more reliable and widely accepted. Pharmaceutical companies, biotech firms, and research institutions actively use CRISPR tools for advanced research and product development. Regulatory and ethical considerations shape adoption and responsible use across regions. A real example includes CRISPR-based therapy used to treat sickle cell disease, where edited cells help patients reduce severe symptoms and improve quality of life.
Download a Free Sample To learn more about this report.
The product segment is projected to grow at a CAGR of 18.78% during the forecast period due to high-fidelity gene editing enzymes, advanced kits & reagents for faster CRISPR workflow standardization, and optimized guide RNA designs that improve targeting precision in complex human and agricultural genomes. Improved guide RNA libraries enhance editing efficiency, supporting broader adoption across therapeutic and research applications globally.
The services segment is expected to grow at a CAGR of 19.03% during the forecast period due to rising outsourcing of CRISPR guide RNA design and validation for complex disease targets. Expansion of GMP-compliant genome editing CRO services supports scalable preclinical workflows. Increasing demand for bioinformatics-based off-target analysis improves safety profiling and speeds regulatory approvals.
Request Customizationto receive a tailored report.
CRISPR/Cas9 led the technology segment with a share of 69.84% in 2025. This dominance is attributed to high gene-editing efficiency, simple guide RNA design, and cost-effective scalability compared to other platforms. Its versatile DNA targeting enables broad therapeutic and agricultural use, while strong clinical validation and established protocols accelerate adoption across research applications.
The prime editing segment is expected to have the fastest growth, registering a CAGR of 19.15% during the forecast period due to its ability to make precise “search-and-replace” DNA corrections without double-strand breaks, reducing genomic damage risks. Its flexibility allows correction of multiple mutation types, expanding use in rare genetic disease models. Improved editing accuracy and lower off-target effects make it highly attractive for next-generation therapeutic development and safer clinical translation.
The pharmaceutical & biotechnology companies segment dominated the CRISPR technology market with a share of 51.06% in 2025. This dominance is attributed to increased CRISPR adoption in drug discovery pipelines, large-scale gene therapy development, and oncology-focused cell engineering programs. Strong investment in clinical trials, proprietary CRISPR platforms, and strategic pharma-biotech collaborations accelerates therapeutic innovation and commercialization across rare and chronic disease treatments.
The contract research organization segment is projected to grow at a CAGR of 20.34% during the forecast period due to rising outsourcing of CRISPR-based preclinical genome screening, where pharma companies delegate high-throughput gene knockout validation to reduce internal R&D burden. Increasing demand for GMP-compliant CRISPR cell therapy testing accelerates clinical readiness. CROs also provide specialized off-target sequencing and bioinformatics safety profiling for regulatory submissions, improving approval efficiency and reducing development risks for gene-editing therapeutics.
Speak to an Analystto discuss market opportunities.
The North America CRISPR technology market accounted for a share of 42.75% in 2025, propelled by early FDA fast-track designations for gene-editing therapies, enabling quicker clinical progression in the US regulatory ecosystem. A strong presence of NIH-funded genome editing research centers accelerates translational studies from lab to clinic, through institutions like the Broad Institute of MIT and Harvard and the National Institutes of Health Intramural Research. Advanced biomanufacturing hubs in Massachusetts and California support scalable GMP production of CRISPR-edited cell therapies, strengthening commercialization and reducing development bottlenecks across regional biotech clusters.
The US CRISPR technology market growth is attributed to hospital-linked genomic biobanks that continuously supply sequenced patient data for target validation through large health systems like Mayo Clinic’s precision medicine database. Strong adoption of Defense Advanced Research Projects Agency (DARPA)-funded gene editing programs also supports high-risk CRISPR innovation for biosecurity and rapid-response therapeutics. The widespread use of cloud-based NIH Genomic Data Commons further supports market growth through collaborative preclinical validations.
The Canada CRISPR technology market is supported by strong federal genomics funding through Genome Canada, which finances large-scale gene-editing research projects across universities and hospitals. The presence of specialized research hubs like the McGill University and University of Toronto CRISPR labs, focusing on rare disease models. Canada’s agricultural biotech programs in Saskatchewan advance CRISPR-based crop resilience research for cold climate conditions. These factors collectively make Canada the fastest-growing country in North America.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific CRISPR technology market is expected to register the fastest growth with a CAGR of 20.88% during the forecast period, due to the rapid adoption of CRISPR tools in large-scale livestock genetic improvement programs in China and Australia, where gene editing is used to enhance disease resistance and productivity in pigs and cattle. Expansion of regional CROs in India and South Korea, which provide low-cost CRISPR screening and preclinical testing services for global biotech firms. Increasing deployment of CRISPR in marine biotechnology, such as algae strain engineering in Japan for biofuel production, further strengthens diversified regional growth.
The China CRISPR technology market is expanding due to large-scale government-backed gene-editing programs integrated into national precision medicine initiatives through state-funded research at the Beijing Genomics Institute, supporting human disease mapping. Rapid commercialization of CRISPR-edited crops like disease-resistant rice developed by the Chinese Academy of Sciences for high-yield farming. China’s strong CRISPR patent filings and industrial biotech clusters in Shenzhen accelerate local innovation and domestic therapeutic development pipelines.
The India CRISPR technology market growth is supported by an expanding contract research organization (CRO) ecosystem, where companies like Syngene International and GVK BIO provide genome editing support for global biotech trials, including CRISPR-based preclinical screening services. Emerging hospital-based genomic medicine units in premier institutes like AIIMS and NCCS Pune, where CRISPR is increasingly used for rare disease diagnostics and translational research. India’s expanding population-scale genome sequencing projects, such as the IndiGen program, provide large genetic datasets that improve CRISPR target identification and support market growth.
The CRISPR technology market is consolidated, with very few leading biotechnology firms dominating due to strong intellectual property, advanced gene-editing platforms, and extensive clinical pipelines. Key players include CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, Beam Therapeutics, and Caribou Biosciences, which lead in developing therapies for genetic disorders, cancer, and rare diseases. Their competitive strength is supported by collaborations with major pharmaceutical companies like Vertex Pharmaceuticals and Regeneron. These firms invest heavily in in vivo editing, base editing, and delivery technologies. Smaller biotech startups focus on niche innovations but face high entry barriers due to patents, regulatory complexity, and costly clinical trials.
In March 2026, CRISPR Technologies raised approximately USD 550 million to advance clinical pipeline and scale commercialization capabilities.
In January 2026, Jawaharlal Nehru Centre for Advanced Scientific Research and CrisprBits signed Letter of Intent (LoI) to establish a Centre of Excellence for CRISPR Innovation in Bengaluru.
In July 2025, Eli Lilly acquired Verve Therapeutics to strengthen pipeline in CRISPR-based cardiovascular therapies.
In May 2025, CRISPR Therapeutics entered into a collaboration with Sirius Therapeutics Collaboration to co-develop siRNA-based therapies for thromboembolic and other diseases.
Customize This Report to Match Your Strategic Objectives
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
We are featured on:
sales@straitsresearch.com